SignalFDA/Bio

Replimune gains accelerated approval of Tudriqev for cutaneous melanoma

Accelerated approval for Tudriqev in melanoma drives high biotech relevance.

What changed

Accelerated approval for Tudriqev in melanoma drives high biotech relevance.

Why it matters

Accelerated approval for Tudriqev in melanoma drives high biotech relevance. — impact context not separately stored; see What changed.

Sources